ProKidney Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $326.3M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.97%
- Volume
- 1.7M
About
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Quick stats
Shares outstanding205.2M
Computed float88.1M
Float / shares42.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001850270
Websitehttps://www.prokidney.com
AI Summary
AI-generated1/6
standardbullishearnings
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
ProKidney reported Q2 2026 financial results, ending the quarter with $181.6 million in cash and marketable securities to fund operations into mid-2027. The company recorded a net loss of $46.4 million, driven primarily by $36.1 million in R&D expenses linked to the ongoing PROACT 1 study.
Operationally, the company completed enrollment for the PROACT 1 accelerated approval efficacy analysis cohort, which includes approximately 320 patients. Topline results for this analysis are anticipated in Q2 2027.
ProKidney appointed Kenneth Locke as Chief Technical Officer, leveraging his 25 years of experience in cell therapy manufacturing and supply chain.
Red flags
- Quarterly net loss of $46.4 million with cash runway extending only to mid-2027.